Lygos

Lygos commercially produces bio-based malonic acid derivatives and specialty chemicals through yeast fermentation. Its publicly disclosed product lines include Soltellus, a biodegradable polymer used in personal care and water treatment, and a malonic acid-based agricultural delivery system that improves nutrient uptake in crops. The company sells these ingredients to formulators and industrial partners rather than directly to consumers.

Lygos has raised over $230 million from a distinctive investor base that includes In-Q-Tel, the venture arm of the CIA, alongside prominent early-stage firms like First Round Capital and IA Ventures. In-Q-Tel's participation, disclosed in 2016, signals potential dual-use applications for Lygos's fermentation platform that extend beyond commercial chemical markets into areas of national security interest.

Lygos uses engineered microorganisms — primarily yeast strains developed through synthetic biology — to convert sugars into specialty chemicals that are conventionally derived from petroleum. The process replaces energy-intensive petrochemical steps with fermentation at ambient temperatures and pressures. Its core platform focuses on malonic acid pathways, a chemical intermediate with broad industrial applications that has historically been expensive to produce via petrochemical routes.

Jay Keasling is a scientific co-founder of Lygos and one of the central figures in synthetic biology, known for engineering yeast to produce artemisinin, an antimalarial drug. Lygos spun out of the Keasling Lab's metabolic engineering research program and maintains deep intellectual ties to the UC Berkeley synthetic biology ecosystem. This relationship provides a continuous pipeline of talent and foundational intellectual property, though the company operates as an independent, venture-backed entity.

Yes. Lygos maintains a dual operational footprint with headquarters in Berkeley, California and an office in Seoul, South Korea. The Seoul presence supports the company's access to Asian fermentation manufacturing capacity and regional commercial partnerships for its bio-based chemical products.

Lygos targets three primary end markets: personal care and fragrance ingredients, agricultural nutrient delivery systems, and biodegradable polymer applications. Its agriculture division, branded Lygos Agriculture, focuses on controlled-release fertilizer technologies. The Soltellus polymer line serves formulators in water treatment and home care. These markets represent large, established chemical segments where bio-based alternatives can compete on both performance and sustainability characteristics.

Lygos is an operating company — an industrial biotechnology firm — not a family office. It is venture-backed, founder-led, and generates revenue through commercial sales of bio-based chemical products to industrial customers. The firm appears in certain alternative asset databases because of its large venture funding rounds and the crossover interest from institutional investors in synthetic biology as an asset class.